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Abstract
Pilocytic astrocytoma (PA) is the most common brain tumor in children. This tumor is usually
benign and has a good prognosis. Total resection is the treatment of choice and will cure
the majority of patients. However, often only partial resection is possible due to the location
of the tumor. In that case, spontaneous regression, regrowth, or progression to a more
aggressive form have been observed. The dependency between the residual tumor size
and spontaneous regression is not understood yet. Therefore, the prognosis is largely
unpredictable and there is controversy regarding the management of patients for whom
complete resection cannot be achieved. Strategies span from pure observation (wait and
see) to combinations of surgery, adjuvant chemotherapy, and radiotherapy. Here, we intro-
duce a mathematical model to investigate the growth and progression behavior of PA. In
particular, we propose a MARKOV chain model incorporating cell proliferation and death as
well as mutations. Our model analysis shows that the tumor behavior after partial resection
is essentially determined by a risk coefficient γ, which can be deduced from epidemiological
data about PA. Our results quantitatively predict the regression probability of a partially
resected benign PA given the residual tumor size and lead to the hypothesis that this
dependency is linear, implying that removing any amount of tumor mass will improve prog-
nosis. This finding stands in contrast to diffuse malignant glioma where an extent of resec-
tion threshold has been experimentally shown, below which no benefit for survival is
expected. These results have important implications for future therapeutic studies in PA
that should include residual tumor volume as a prognostic factor.
Author Summary
The most common brain tumor in children and young adults is pilocytic astrocytoma
(PA). This tumor is usually benign and often follows an indolent course. The treatment of
choice is resection and the prognosis is very favorable if total excision can be achieved.
However, due to the location of the tumor, only partial resection is possible in many cases.
Partially resected PA could spontaneously regress, regrow or even progress to a more
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aggressive type of PA. We develop a mathematical model which describes the growth, pro-
gression and regression of PA. We are able to quantitatively predict the chance for regres-
sion in dependency of the remaining tumor size. This prediction has the potential to
provide decision support to clinicians after partial resection of benign PA. Furthermore,
our results imply that there is no resection threshold for PA below which no survival
advantage is provided. This finding stands in contrast to malignant brain tumors where
such a threshold has been experimentally shown.
Introduction
Pilocytic astrocytoma (PA) is the most common pediatric brain tumor and the second most
frequent tumor in childhood [1]. Three of four cases are diagnosed up to an age of 20 years
with the highest age incidence between 5 and 15 years. PA is usually benign, often follows an
indolent course and is mostly slow-growing [2]. In children, PA most frequently occurs in the
cerebellum but can develop in the entire neuroaxis. Surgery is the treatment of choice [3]. If
total excision is achieved, the prognosis is favorable with more than 90% of patients being
cured [4]. However, in many cases tumor location in critical or deep areas (such as brain stem,
optic pathway, or hypothalamus) restricts resection options and alternative management
options are required [5, 6]. Patients with only partial resection have a worse and highly unpre-
dictable prognosis [4, 5]. Tumors can regrow or even progress to a more aggressive tumor [3,
7–11] but spontaneous tumor regression of PA has also been observed [4, 12–15] and is a com-
mon phenomenon. A recent review in [14] estimates a fraction of 14% of all residual cerebellar
astrocytoma that regress spontaneously. Other studies claim an even higher portion [16].
While regression of PA after partial resection is reported in many case series [12–16], the influ-
ence of the residual tumor size has not been evaluated yet. Moreover, the management for
patients in whom complete resection cannot be achieved is still unclear. Due to the chance of
regression and the indolent nature of PA, some authors propose a wait and see strategy in
order to avoid potential risks induced by further therapies [4, 7, 14]. Other authors favor an
aggressive surgical resection in combination with additional treatment strategies, like radiation
and chemotherapy to control tumor growth [15, 17, 18].
On the molecular level, it has been shown that activation of the mitogen-activated protein
kinase (MAPK) pathway is sufficient to induce the development of PA. This leads to the
hypothesis that PA is a single-pathway disease [19, 20]. Furthermore, PA usually harbor only
one alteration within the MAPK pathway. The majority of mutations are activating changes in
the BRAF gene, the most common is the KIAA1549-BRAF fusion, but also other activating
mutations have been described. A more aggressive behavior of PA is observed if additional
genetic alterations occur, e.g. loss of tumor suppressor gene CDKN2A [10, 21]. Furthermore,
alterations in the PI3K/AKT pathway [22] have been associated with aggressive forms of PA
[9]. One proposed mechanism for the often observed slow growth of the tumors is oncogene-
induced senescence, which is a mechanism limiting neoplastic growth by inducing cellular
senescence. The MAPK activation might initially promote growth as well as induce senescence.
Oncogene-induced senescence has also been observed in melanocytic nevi and melanoma [10].
Several mechanisms for tumor regression have been suggested, e.g. immunologic mecha-
nisms, hormonal factors, induction of differentiation or apoptosis [13]. However, the reason
why regression in PA occurs is not understood yet [4].
We formulate a mathematical model for growth, progression and regression of PA based on
the above described clinical and molecular biological observations. We study the effects of
Model of Spontaneous Tumor Regression in Pilocytic Astrocytoma
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004662 December 10, 2015 2 / 17
competition between tumor and wild-type cells on the chance for regression. We distinguish
two types of PA. Benign cases are classified as PA-I tumors and assumed to be caused by alter-
ation of a single pathway. Tumors in which an additional alteration occurs are categorized as
PA- II tumors, representing the more aggressive subset of PA. We introduce a stochastic tumor
growth and progression model, namely a MORAN model [23] with mutations. We chose a
MORAN model in this juvenile tumor, since astrocyte proliferation and diversification mainly
happen during late embryogenesis and the first three weeks after birth. These processes are
largely complete by early postnatal stages, while early and late postnatal development is mainly
characterized by maturation processes (like continuing elaboration of astrocyte processes and
building of synaptic/vascular connections) [24, 25]. Since PA are usually diagnosed between 5
and 15 years, the normal astrocyte population is not proliferating at this time anymore. There-
fore, it is reasonable to assume an approximately homeostatic tissue. In such a tissue, MORAN
dynamics provide a natural and established framework for modeling competition between
tumor and wild-type cells.
In our model, we derive the PA-regression-function describing the probability for regres-
sion in dependency of the residual tumor size after partial resection of benign PA. The accumu-
lation of mutations in a tissue has been modeled and investigated by several authors by using a
MORAN model. Work by IWASA, MICHOR, KOMAROVA and NOWAK [26, 27] has been extended by
SCHWEINSBERG [28] and DURRETT, SCHMIDT and SCHWEINSBERG [29] to the case ofmmutations.
These models analyze tumor growth and progression [30–34] with a focus on theoretical
results regarding the waiting time until a cell has accumulated a certain number of mutations.
Our approach is motivated by a concrete clinical question which is the regression probability
of a benign PA tumor in dependency of the residual tumor size. We modify the model intro-
duced in [29]. In particular, we consider MORAN dynamics with two mutations but two absorb-
ing states and investigate the precise relation of the two absorption probabilities which allows
the incorporation of epidemiological data to calibrate the model. From the mathematical point
of view, the relation of the two absorption probabilities can be connected to the portion of sto-
chastic tunneling events in the model presented in [29].
Materials and Methods
Definition of a tumor growth and progression (TGP) model
State space and representation of PA tumors. We use a MORAN model with mutations to
model tumor growth, regression and progression of PA. The model incorporates three cell
types, wild-type cells, type-I cells and type-II cells. Wild-type cells have no genetic alteration.
Type-I cells are characterized by a MAPK pathway alteration. We assume that type-I cells pro-
liferate without fitness advantage. This is motivated by the observation that benign PA grow
very slowly, can be stable in size over a long time period or even regress. Type-II cells have
acquired a second genetic alteration disabling oncogene-induced senescence, for example by
loss of CDKN2A. Due to their aggressive behavior, we assume a very large fitness advantage of
type-II cells. The parameter N in our model represents a critical tumor size in the sense that a
PA which reaches size N cannot spontaneously regress. Our assumption that such a critical size
exists is founded on clinical data and observations which are explained later. Here, we focus on
the chance of tumor regression of a partially resected benign PA in dependency of the residual
tumor size. Therefore, we do not consider growth of tumors beyond the critical size N since
spontaneous regression would not be possible anymore in such a case. Spatial aspects are
neglected so that the number of cells of each cell type is sufficient to describe the states of our
model. Therefore, the state space can be described by S = {0, 1, 2,...., N, E}. Here, states 0 to N
represent the occurrence of the respective number of type-I cells and no type-II cell. The
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additional state E indicates the presence of a type-II cell. States N and E are absorbing states of
the model and represent the occurrence of a benign PA which we call PA-I tumor and an
aggressive form of PA named PA-II tumor, respectively. Hence, the occurrence of a PA-I
tumor is represented by the accumulation of N type-I cells. As soon as a single type-II cell
appears, we identify this state as occurrence of a PA-II tumor which is modeled as absorption
in state E. Please note that no transition from state N to state E is possible in the model. Fig 1
illustrates the three cell types and the representation of both types of PA tumors in the model.
Dynamics in the model. The dynamics of our model incorporates cell death, proliferation
and genetic alterations. Cell death and proliferation are modeled according to the MORAN
dynamics [23] as follows. Two cells are chosen randomly. One of these cells undergoes cell
death and the other cell proliferates. The offspring of the proliferating cell substitutes the cell
chosen for death. Since we neglect spatial aspects, the offspring of a cell can replace any other
cell. During proliferation, a mutation of the new-born cell can occur. Wild-type cells mutate to
type-I cells with probability u and these mutate to type-II cells with probability v. Moran
dynamics is defined with respect to a relevant cell number which describes the number of cells
that potentially compete with each other. This relevant cell number can be assumed to be
approximately equal to the critical tumor size N based on the following arguments. Since PA
tumors grow as a solid, well-circumscribed mass within the normal brain, new tumor cells are
placed in the vicinity of already mutated cells. Similarly, only wild-type cells in the vicinity of
mutated cells can potentially compete with tumor cells. Thus, the actual relevant cell number
for the MORAN dynamics is somewhere between the critical tumor size N and the total number
of astrocytes in the brain but clearly much closer to N. Since there is no detailed experimental
estimate of this number so far, we assume in our model that the relevant cell number for
MORAN dynamics is equal to N. Although we do not explicitly incorporate spatial aspects, this
assumption implicitly incorporates spatial aspects by implying that tumor cells cannot place its
offspring too far away.
We assume that initially all cells are wild-type cells. Hence, the process starts in state 0. The
number of type-I cells changes according to the above described dynamics. The precise rates of
the process are provided in S1 Text and the dynamics are illustrated in Fig 1.
The described model is called TGP process and the corresponding stochastic process is
denoted by (Xt)t  0. The TGP process is a MARKOV process with two absorbing states N and E
representing a PA-I tumor and a PA-II tumor, respectively. Hence, the absorption probabilities
of the TGP process in both states correspond to the clinically observed fraction of PA-I and
PA-II tumors. Therefore, we will derive these absorption probabilities and analyze in which
way they depend on the model parameters N, u and v. Furthermore, we assume that tumor
regression is characterized by the vanishing of all tumor cells. Hence, tumor regression corre-
sponds to reaching state 0 in the TGP model which will be described by a tumor regression
function in the following.
Analysis of the TGP process
The behavior of the TGP process depends on its three parameters, the critical tumor size N, the
mutation probability from wild-type cells to type-I cells u and the mutation probability from
type-I cells to type-II cells v. The parameter regime for the analysis of the TGP model is chosen
such that
u 1
N
ð1Þ
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Fig 1. States and dynamics in the TGPmodel. A. The initial state of the TGPmodel is all-cells-wild-type. Type-I cells (black cells) can arise due to type-I
mutations. If the number of type-I cells reaches at least the critical tumor sizeN, a PA-I tumor developed which cannot regress anymore (black box). We
assume that a PA-II tumor occurs as soon as the first type-II cell appears in the system (red box). Solid arrows indicate a single transition whereas dotted
arrows indicate several transitions.B. Wild-type cells mutate to type-I cells with probability u and type-I cells mutate to type-II cells with probability v during
proliferation. Cell death and proliferation are included as follows. A cell is randomly chosen for cell death and replaced by the offspring of another randomly
chosen cell. Spatial aspects are neglected in the model.
doi:10.1371/journal.pcbi.1004662.g001
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and
ðN ﬃﬃvp Þ2 ¼: g > 0: ð2Þ
In the following we explain this choice. We call the parameter γ risk coefﬁcient.
Decomposition of the TGP process into two sub-processes. Assumption Eq (1) implies
that type-I mutations are rare. Typically, an emerging type-I lineage either goes extinct or leads
to absorption of the TGP process before another type-I mutation occurs. Hence, each newly
arising type-I mutant can be investigated independently. This idea has been introduced in [29].
Therefore, we set u = 0 as soon as type-I cells are present, i.e. if the TGP process is in state k, 1
 k N. Since absorption is inevitable in the TGP model, a successful type-I mutant that leads
to absorption in state N or state Emust eventually occur. Before the occurrence of this specific
type-I mutant, unsuccessfulmutants arise and go extinct driving the process back to state 0.
Hence, assumption Eq (1) implies that a PA tumor develops from a single mutated cell. See
also Fig 2 for an illustration of this decomposition of the TGP model.
Absorption probability of the TGP process. As Fig 2 illustrates, the absorption probabili-
ties of the TGP model agree with those of the sub-process starting with emergence of the suc-
cessful mutant. This sub-process is formally defined in S1 Text, where also a detailed
derivation of the absorption probability in state N of the TGP model is provided. This deriva-
tion utilizes first step analysis in order to obtain a linear system of equations for the absorption
probabilities starting with k, 1 k N, type-I cells. Subsequently, CRAMER’S rule, see equation
(S4) in (S1 Text), allows to derive the particular absorption probability starting with one type-I
mutant. Taking the limit for N!1 leads to the asymptotic absorption probability in state N
given by
aðgÞ ¼ 1
I0ð2
ﬃﬃ
g
p Þ ; ð3Þ
where In; n 2 IN0; denote the modiﬁed BESSEL functions of the ﬁrst kind, see [35]. A plot of α(γ)
is given in S1 Fig. The absorption probability α(γ) corresponds to the fraction of PA-I tumors
Fig 2. Decomposition of the TGP process. Assumption Eq (1) implies that no other PA-I mutation occurs if type-I cells are already present in the system.
Therefore, u can be set to zero when a single type-I cell emerged. This allows to decompose the process into two sub-processes. First, occurrence of
unsuccessful mutants, which go extinct and, second, the occurrence of a successful mutant which leads to absorption in one of the PA states.
doi:10.1371/journal.pcbi.1004662.g002
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in the TGP model. Three different behaviors regarding absorption can be distinguished in
dependency of the parameters N and v.
1. If
ﬃﬃ
v
p  1N , then the system is primarily absorbed in state E. The assumption guarantees that
the number of type-I cells is only a small fraction of the critical number of mutated cells N
throughout the process so that the probability of reaching state N can be neglected. The
probability that a single arising type-I cell reaches fixation is approximately 1N . This is much
smaller than
ﬃﬃ
v
p
, which is asymptotically the probability that this cell produces a type-II cell
before going extinct.
2. If
ﬃﬃ
v
p  1N , then the system is primarily absorbed in state N. In this case, it is unlikely that a
type-II cell appears before the system reaches state N so that the probability of reaching
state E vanishes.
3. If ðN ﬃﬃvp Þ2 ¼ g > 0, then the system can be absorbed both in state N and in state E. In this
case a mutation to a type-II cell occurs with positive probability before state N is reached.
For rigorous proofs of these results see [29] and for a good sketch of the proofs without
technical details see [36].
To model growth and progression of PA, we focus on the third case since this parameter
regime implies strictly positive absorption probabilities in both absorbing states N and E.
Hence, both PA-I and PA-II tumors occur with positive probability in the model which justifies
assumption Eq (2).
Derivation of tumor regression functions in the TGPmodel
We are interested in the regression probability of a partially resected PA-I tumor in depen-
dency of the remaining tumor size and assume that regression of a residual tumor is achieved if
no tumor cells are present anymore. All suggested mechanisms of tumor regression influence
the ratio of tumor and wild-type cell birth and death rates. Therefore, we assume that competi-
tion between tumor and wild-type cells leads to tumor regression which is incorporated by
MORAN dynamics with relevant cell number equal to N again, see also Fig 3. Furthermore, we
assume that the partial resection reduces the residual number of PA-I cells below the critical
tumor size N. Hence, the regression function is defined as the extinction probability of tumor
cells, i.e. the probability to reach state 0 when starting the TGP process in some state k with 1
 k N − 1. For v = 0, our TGP process simplifies to a neutral two-type MORAN process in
which the extinction probability is an established result and equals 1 k
N
[32]. Here, we derive
this extinction probability for our TGP process with three cell types. For the mathematical
analysis, it is convenient to express this function in terms of r ¼ k
N
. The fraction ρ describes the
ratio between the residual number of PA-I cells after partial resection k, 1 k N − 1, and the
critical tumor size N.
Formally, these considerations lead to the regression function bNg ðrÞ deﬁned as
bNg ðrÞ :¼ IPðXt ¼ 0 for some t  0jX0 ¼ NrÞ; r 2 ½0; 1: ð4Þ
Fig 3 provides a graphical representation of regression in the TGP model.
A diffusion approximation of (Xt)t  0 leads to the WRIGHT-FISHER diffusion process that can
be utilized to approximate the term of Eq (4). This approach was introduced in [29] and leads
finally to a series representation as approximation of bNg ðrÞ. In S1 Fig it is shown that this series
can be expressed by BESSEL functions In; n 2 IN; [35] and that the regression function of the
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TGP model is given by
bgðrÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 rp I1 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
gð1 rÞp 
I1ð2
ﬃﬃ
g
p Þ ð5Þ
for 0 ρ 1. The graph of βγ is plotted in Fig 4C for different values of the risk coefﬁcient γ.
TAYLOR expansion of the tumor regression function. In order to estimate the deviation of
the specific tumor regression function for PA from a linear function, we derive the first order
TAYLOR polynomial T1(ρ) at ρ = 0.5 of the regression function Eq (5) and an estimation of the
Fig 3. Tumor regression in the TGPmodel. A. Partial resection of a PA-I tumor reduces the number of
tumor cells to size k which is assumed to be below the critical tumor sizeN. The residual tumor can regrow,
progress or regress based on the same dynamics that led to the primary tumor. Hence, the TGP dynamics
with relevant cell numberN is utilized to describe the further development of the residual tumor. Regression is
achieved if state 0 is reached, i.e. no tumor cells are present anymore.B. The red area indicates the resected
part of the diagnosed PA-I tumor. This resection leads to removal of both tumor and wild-type cells.
Subsequently, the residual number of tumor cells k competes with other wild-type cells which can lead to
regrowth, regression or progression of the residual tumor. We assume thatN is the relevant cell number for
this competition as in the formation of the primary tumor. This relevant cell number is indicated by the blue
circle.
doi:10.1371/journal.pcbi.1004662.g003
Model of Spontaneous Tumor Regression in Pilocytic Astrocytoma
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004662 December 10, 2015 8 / 17
Fig 4. Parameter estimation from epidemiological data and derivation of the PA-regression-function. A. In order to estimate the clinically observed
fraction of PA-I, we utilize data from the literature. B. The estimated fraction of PA-I cases p^ is interpreted as absorption probability in state N in our model. Eq
(3) allows to estimate the corresponding risk coefﬁcient g^. C. Substituting the estimated risk coefﬁcient g^ ¼ 0:152 in Eq (5) determines the PA-regression-
function β0.152(ρ) which is plotted in purple. Furthermore, the blue plots indicate the corresponding regression functions for values of γ which are obtained
within the standard deviation of p^.
doi:10.1371/journal.pcbi.1004662.g004
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remainder term R1(ρ). It holds that
T1ðrÞ ¼
I1ð
ﬃﬃﬃﬃﬃ
2g
p Þ
ﬃﬃﬃ
2
p
I1ð2
ﬃﬃ
g
p Þ 
ﬃﬃﬃ
2
p
I1ð
ﬃﬃﬃﬃﬃ
2g
p Þ þ ﬃﬃgp ðI0ð
ﬃﬃﬃﬃﬃ
2g
p Þ þ I2ð
ﬃﬃﬃﬃﬃ
2g
p ÞÞ
2I1ð2
ﬃﬃ
g
p Þ ðr 0:5Þ;
jR1ðrÞj 
g
8
;
ð6Þ
for ρ 2 [0, 1]. The Supplementary Information, (S1 Text), provides a detailed derivation.
Results
Derivation of the PA-regression-function
The regression function Eq (5) depends on the parameters of the TGP model via the risk coeffi-
cient γ, see Eq (2). This parameter is estimated such that the clinically observed fraction of
PA-I tumors, denoted by p^, equals the theoretically obtained fraction α(γ) of absorption in
state N in the TGP model. Subsequently, the derived risk coefﬁcient is substituted into the
regression function given by Eq (5) in order to obtain the speciﬁc PA-regression-function. Fig
4 summarizes the overall strategy of this approach.
We estimate the clinically observed fraction of PA-I tumors on the basis of data reported in
[10]. The authors analyzed 66 PAs with respect to their genetic profile and classified 57 cases as
benign PA-I tumors and 9 cases as more aggressive PA-II tumors. This leads to
p^ ¼ 57
66
¼ 0:8636:
In the TGP model, this clinically observed fraction corresponds to the absorption probability
in state N, given by Eq (3). Therefore, we set
aðg^Þ ¼ p^ ¼ 0:8636:
This equation allows to calculate the risk coefﬁcient g^ which yields
g^ ¼ 0:152:
Substituting g^ ¼ 0:152 into the regression function given by Eq (5) allows to derive the PA-
regression-function given by
b0:152ðrÞ ¼ 2:3795
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 rp I1ð0:7797
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 rp Þ; 0  r  1: ð7Þ
A plot of this function is provided in Fig 4C. This ﬁgure shows that the regression function is
very robust to small alterations with respect to p^.
Note that the actual risk coefficient may be smaller than the estimated value g^ ¼ 0:152 due
to the following considerations. The parameter N in our model represents a critical tumor size
above which tumor regression cannot be expected anymore. However, the number of mutated
cells in a diagnosed PA-I tumor may be larger than N because tumors could grow beyond this
critical size without symptoms or due to a diagnostic gap between ﬁrst symptoms and diagno-
sis. Therefore, a PA-I tumor can consist of more than N type-I cells and should have been
more susceptible for progression to PA-II than accounted for in our TGP model. Hence, the
risk of progression in our TGP model and therefore g^ might be overestimated. However, this
would not change the linear dependency between residual tumor size and regression probabil-
ity which is discussed in the following.
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Linear dependency between residual tumor fraction and regression
probability of PA
We can show that the PA-regression-function Eq (7) is approximately linear by utilizing a TAY-
LOR expansion using Eq (6). Substituting the estimated risk coefficient of the PA-regression-
function g^ ¼ 0:152 into Eq (6) leads to
T1ðrÞ ¼ 0:9817 r; r 2 ½0; 1: ð8Þ
This is a very good approximation since the remainder term can be estimated by
jR1ðrÞj 
g
8
¼ 0:152
8
¼ 0:0185 ð9Þ
for ρ 2 [0, 1]. Hence, the deviation of the PA-regression-function from the linear function
T1(ρ) is very small. Moreover, if the risk coefﬁcient was overestimated, an even smaller devia-
tion would be observed as Eq (9) implies.
Quantitative prediction of the regression probability for benign PA
In order to provide a quantitative prediction of the regression probability given the absolute
residual tumor size, we estimate the critical tumor size N in our model. Since the total cell num-
ber corresponds to the the tumor volume, we can interpret N also as minimum absolute tumor
volume above which tumor regression cannot be expected anymore. The existence of this criti-
cal tumor size and its estimate of a cell number corresponding to a volume of 9 cm3 is justified
in the following way. First, an extensive literature research indicated that tumor regression for
residual cerebellar PA over 9 cm3 has not been reported yet, see S1 Table. Second, the predic-
tion for patients with 78 cerebellar astrocytoma, including 62 PAs, has been investigated in
[15]. Fig. 6 in [15] implies that the theoretical proportion of progression-free patients based on
a Cox regression analysis with a residual tumor of 9 cm3 is estimated to be zero in the long-
term. Finally, in [18], the role of the extent of resection in the long-term outcome of low-grade
gliomas is investigated including 93 PAs. It is stated that “‘the predicted outcome for patients is
negatively influenced by even residual tumor volumes on the order of 10 cm3”’.
Incorporating the estimation for the critical tumor size of 9 cm3 into the PA-regression-
function Eq (7) allows to quantify our predictions, indicating that any volume reduction of one
cm3 below the critical size will add 10% to the chance for regression (see also Fig 5 and
Table 1).
Non-existence of an extent of resection (EOR) threshold
In malignant brain tumors it has been shown that there is an EOR threshold below which no
survival advantage is provided, e.g. in glioblastoma this threshold is 78% [37]. The existence of
different tumor zones which basically reflect tumor heterogeneity is one proposed reason for
such a threshold in malignant brain tumors [38]. In contrast, our results suggest the non-exis-
tence of such a threshold in PA. This is an immediate consequence of the linear dependency
between residual tumor size and regression probability. If the residual tumor is smaller than
the critical tumor size N, which marks the volume for which regression cannot be expected
anymore, any reduction of the tumor volume will contribute to the regression probability.
Importantly, this behavior stands in contrast to a non-linear dependency which would have
been obtained in our model for a higher estimated risk coefficient γ, see Fig 5.
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Table 1. Predicted regression probability for cerebellar PA based on the absolute residual tumor size.
Residual tumor size (cm3) Tumor regression probability (in %)
0.1 98.91
0.5 94.06
1 88.16
2 76.50
3 65.03
4 53.75
5 42.64
6 31.71
7 20.47
8 10.39
The values in this table are derived from the PA-regression-function provided by Eq (7) and use an
estimate for the critical tumor size of 9 cm3. The PA-regression-function is also illustrated in Fig 5.
doi:10.1371/journal.pcbi.1004662.t001
Fig 5. Non-existence of an EOR threshold in PA. The derived PA-regression-function (purple line) allows
to quantitatively predict the regression probability based on the critical tumor size estimated as 9 cm3, see
also Table 1. Roughly, one cm3 of resected tumor mass will elevate the chance of regression by 10%. The
direct consequence is the non-existence of an EOR threshold implying that any proportion of resected tumor
mass will improve prognosis. This stands in contrast to the behavior of the regression function for a fictive
high value of the risk coefficient of e.g. γ = 50 (black line).
doi:10.1371/journal.pcbi.1004662.g005
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Discussion
In order to gain insights into the regression behavior after partial resection of benign PA, we
introduced a stochastic TGP model based on recent molecular findings, functional, and clinical
data. We derived a regression function that depends on the risk coefficient γ and quantifies the
probability of regression in dependency of the residual tumor size. By incorporating epidemio-
logical data on the clinically observed fractions of PA-I and PA-II cases, we estimated γ and
derived the specific PA-regression-function, given by Eq (7). The estimated PA-regression-
function implies an approximately linear dependency between the residual critical tumor frac-
tion and the regression probability as illustrated in Fig 4C. This linear dependency is supported
by a TAYLOR approximation and an estimation of the remainder term, given by Eqs (8) and (9),
respectively. Furthermore, we quantitatively predicted the chance for tumor regression for
benign PA by estimating the critical tumor size N, see Table 1.
Our TGP model incorporates assumptions based on clinical observations. It is observed in
the clinics that PA-I tumors grow slowly, arrest in growth, or even regress. Hence, type-I
cells in our model proliferate without fitness advantage. Furthermore, we assume that the
first type-II cell that occurs leads to an aggressive form of PA, corresponding to malignant
progression in PA. Alternatively, one could assign a success probability s to an emerging
type-II cell, which represents the probability that a single type-II cell leads to a PA-II tumor.
However, it has been shown in [36] that this is equivalent to considering an analog process
with type-II mutation probability sv instead of v. This alternative process would lead to the
same estimated risk coefficient g^. Therefore, the estimated PA-regression-function would
not change since this function is determined only by g^. Further, we use asymptotic results for
N!1 in order to calculate the theoretical portion of PA-I and PA-II cases in the TGP
model. This is justiﬁed by the fact that a tumor consists of billions of cells. Simulation results
given in S2 Table support these asymptotic results. They show that excellent accordance with
formulas for ﬁnite N is reached even for small values of N. Moreover, we could show that the
model is robust against small changes in the proportion of PA-I versus PA-II tumors as
shown in Fig 4C. This robustness is an important property of the model since the proportion
of PA-I can vary between different studies, especially since the sample size is often very small
[39, 40].
To our knowledge, the proposed TGP model is the first theoretical attempt to predict the
regression behavior of PA. In particular, we analyzed PA regression based on the population
dynamics of tumor and wild-type cells. The ratio of tumor cell birth and death rates is influ-
enced by immunologic mechanisms, hormonal factors, induction of differentiation, or apo-
ptosis, which could all contribute to tumor regression [13]. Since PA-I tumors grow very
slowly, we assumed identical birth and death rates of type-I cells in our model.
Our findings have clinically relevant implications. There is still controversy about the best
treatment strategy for PA. Since PA is a slowly growing tumor and might even spontaneously
regress, a wait and see strategy is an option besides more aggressive treatment strategies like
radiation and chemotherapy. The decision for a more radical therapy would depend on the risk
for recurrence (or even progression) and the chance of regression. However, long-term follow-
up data about the probability of regression or progression after partial resection of PA is
restricted and only retrospective studies with small case numbers are available [39–42]. The
linear dependency between residual tumor size and regression probability in our model implies
that every resected percentage point of a PA-I tumor contributes equally to the regression
probability. Hence, there is no EOR threshold, but any small reduction in tumor mass provides
an improvement in prognosis by increasing the probability for tumor regression. This predic-
tion suggests a fundamentally different treatment strategy for PA compared to glioblastoma for
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which such a threshold has been determined [37]. Therefore, our results indicate that resection
of a tumor should be aimed at even if a complete resection may not be possible. This is sup-
ported by studies showing that in patients with PA outcome depends on the extent of resection,
although these studies only differentiate between biopsy, partial, subtotal, and gross/total resec-
tion and do not measure tumor volumes [3, 15, 16]. Moreover, if complete resection cannot be
achieved, our results predict that the outcome linearly depends on the residual tumor volume.
If there is a reasonable chance for regression of the residual tumor, it might be less justified to
accept side effects by further therapies like radiation. This is an important result since the role
of additional radiation therapy in treating children with tumors is highly controversial [8].
Unfortunately, as far as we know, there are no clinical studies on treatment of PA that take into
account the influence of the residual tumor volume on patient outcome. We suggest that the
residual tumor volume is an important prognostic marker and that a lack of sufficient volumet-
ric data could be a reason for different results in clinical studies on additional treatment in PA.
The results of this work should be further supported by future clinical studies that include
volumetric data, which will improve the quantitative prediction of our model and form a statis-
tical basis for clinical decision rules.
Supporting Information
S1 Text. Supplementary information. The supplementary text contains detailed information
about: 1) transition rates of the TGP model; 2) detailed derivation of the absorption probabili-
ties; 3) derivation of the asymptotic absorption probabilities of the TGP model; 4) derivation of
the regression function; 5) TAYLOR expansion of the regression function.
(PDF)
S1 Fig. The asymptotic absorption probability in state N in dependency of the risk coeffi-
cient γ. The asymptotic absorption probability α(γ) in state N is strictly monotonically decreas-
ing. The clinically observed fraction of PA-I cases is estimated as p^ ¼ 0:8634 and the
corresponding risk coefﬁcient is g^ ¼ 0:152.
(TIF)
S1 Table. Residual cerebellar postoperative PA volume and outcome. This table contains the
results of our literature research about volumetric data of residual cerebellar PA and the corre-
sponding patient outcome.
(PDF)
S2 Table. Comparison of theoretical absorption probabilities and simulation results. This
table shows the exact absorption probabilities αN(γ) in state N compared to the results from
10000 simulations of trajectories of the TGP process (Xt)t  0 and the asymptotic absorption
probabilities α(γ). The asymptotic values are in good accordance with both, the exact theoreti-
cal values and the simulation results. Furthermore, the asymptotic result α(γ) is a good approx-
imation even for small N.
(PDF)
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